Figure 3 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Year: 2026
Type: other
Abstract: Imaging following intratumoral (IT) and intravenous (IV) VV1. A, CT images of the thoracic region of a 57-year-old patient with thymic carcinoma following a 30-minute intravenous infusion of VV1 (1.7 × 1010 TCID50) + labeled dose/regimen of avelumab (part 3). In the opinion of the investigator, only scar tissue remained at the last assessment (August 2021). B, SPECT/CT/NIS imaging of 75-year-old male patient with adenocarcinoma (unknown primary cancer) following intratumoral (IT) administration of VV1 (3 × 108 TCID50) monotherapy (part 1). C, SPECT/CT/NIS imaging of a 62-year-old male patient with mesothelioma following IT administration of VV1 (1 × 108 TCID50) monotherapy (part 1). D, Immune cell infiltrates and PD-1 in a male patient with head and neck squamous cell (HNSCC) with SD, following IT administration of VV1 (part 1). Images are of an injected lesion. E, Immune cell infiltrates and PD-1 in a 70-year-old male patient with HNSCC with SD, following IT administration of VV1 (3 × 106 TCID50) monotherapy (part 1). Top, baseline. Middle, injected lesion. Bottom, noninjected lesion.
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7202213029
Cites:
Cited by:
Related to: